PLK3

Across TCGA pan-cancer cohorts, PLK3 RNA differs between tumor and matched normal tissue in 14 of 18 cancer types tested, making tumor–normal expression one of PLK3’s most consistent transcriptional readouts.

The strongest signal is observed in thyroid carcinoma (THCA), where PLK3 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types PLK3 is over-expressed in tumor, although a few such as KICH and BRCA show the opposite, repressed pattern.

THCA, COAD, and KIRC are the cancer types where PLK3 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PLK3 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
THCA	Male	III,IV	+1.664	<.001	11	view →
COAD	Female	All	+1.238	<.001	10	view →
KIRC	All	All	+0.744	<.001	9	view →
KICH	Female	II,III,IV	−2.584	<.001	8	view →
BRCA	Female	II,III,IV	−0.714	<.001	8	view →
LUSC	Female	All	−1.459	<.001	6	view →
BLCA	Female	III,IV	−1.192	.007	6	view →
UCEC	All	All	−1.016	<.001	4	view →
LUAD	All	All	−0.584	<.001	3	view →
CHOL	Male	All	+1.823	.007	2	view →
PRAD	All	All	−0.600	<.001	2	view →
LIHC	All	All	−0.514	.016	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 14 lineages.

PLK3–THCA

Open the THCA breakdown →